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Docetaxel (Taxotere
s), alone or in combination with other anticancer agents, has proven efficacy in the first- and second-line
treatment of metastatic breast cancer. This phase II study investigated the efficacy and tolerability of docetaxel as neoadjuvant
chemotherapy in women with stage II–III primary operable breast cancer. Patients (n¼88) were treated with six cycles of docetaxel
at 100mgm
 2 every 21 days, followed by definitive surgery and radiotherapy. After six cycles of docetaxel, the overall clinical
response rate was 68.4% (CI 95%: 58.1–78.7%), including 19.0% complete remissions. Breast conservation was achieved in 72.4% of
patients. A high pathological complete response (pCR) rate in breast was confirmed in 15 patients (19.8% (CI 95%: 10.8–28.8%)) on
Chevallier’s classification restricted to breast and in 27 patients (35.5% (CI 95%: 24.7–46.3%)) on Sataloff’s classification. After a
median follow-up of 30.8 months, 19 recurrences were documented with a median time to first recurrence of 17.3 months. Patients
with stage III tumours had more recurrences than patients with stage II tumours (P¼0.02). The principal toxicity of docetaxel is
myelosuppression and 70.5% of patients developed grade III or IV neutropenia with 13.6% developing neutropenic sepsis. There was
no case of severe cardiac toxicity, thrombocytopenia or any other serious adverse events. In conclusion, neoadjuvant docetaxel
induces a high pCR and breast-conservation rate. Docetaxel monotherapy is a highly effective regimen that merits formal comparison
with currently used combination regimens in a randomised phase III study.
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The goal of chemotherapy given in the adjuvant or neoadjuvant
(preoperative) setting is to eradicate occult distant metastases and
to increase ultimately the probability of disease-free survival (Bear,
1998; Gradishar, 1999). Systemic therapy has been used for many
years as a primary treatment in locally advanced or inflammatory
breast cancer. More recently, the value of neoadjuvant chemother-
apy has been recognised and extended to operable breast cancer
for tumours that are too large to be treated immediately by
conservative surgery. The aim of neoadjuvant chemotherapy is to
reduce tumour size before surgery, and hopefully result in a lower
rate of total mastectomy. Breast-conservation therapy can be
performed in 450% of all cases, despite a nonnegligible rate of
local recurrences (23.1 vs 8.7% for patients treated by adjuvant
chemotherapy), without compromising patients’ outcome (Maur-
iac et al, 1991). The quality of patients’ response to this strategy,
which is usually followed by locoregional therapy (surgery and/or
radiotherapy), seems to be a prognostic factor in many studies
(Scholl et al, 1991; Calais et al, 1994; Bonadonna et al, 1998; Brenin
and Morrow, 1998; Ferriere et al, 1998). This has become a
common approach for the treatment of a variety of neoplasms,
including oesophageal, testicular, lung and breast cancers,
osteosarcoma and squamous cell cancers of the head and neck.
Neoadjuvant chemotherapy in patients with operable breast
cancer needs to be evaluated in prospective clinical trials before it
is firmly established as the standard clinical practice (Mamounas,
1998). Furthermore, information on the differential histological
responses of primary breast tumours and axillary metastases to
neoadjuvant chemotherapy is limited (Chevallier et al, 1993;
Sataloff et al, 1995; Chollet et al, 1997). Currently, only a small
number of studies have published data concerning the number and
outcome of patients with a complete pathological response of both
the primary tumour and axillary lymph nodes after neoadjuvant
chemotherapy (Feldman et al, 1986; Fisher and Mamounas, 1995,
1997; Kuerer et al, 1999).
Docetaxel has been shown to be one of the most active cytotoxic
agents. It is a promising candidate for new therapeutic strategies in
patients with breast cancer, and is therefore potentially useful for
neoadjuvant chemotherapy (Cortes and Pazdur, 1995; O’Leary et al,
1998; Costa et al, 1999). As a single agent, docetaxel has shown
marked clinical activity in the treatment of anthracycline-resistant
and chemotherapy-naı ¨ve (for metastatic disease) breast cancer,
achieving response rates of 34 and 50–72%, respectively (Ravdin
et al, 1995; Valero et al, 1995; Marty et al, 1997; Valero, 1997). In a
randomised phase III trial in first-line metastatic breast cancer
docetaxel (100mgm
 2) exhibited superior efficacy and tolerability
compared with doxorubicin (at the optimal dose of 75mgm
 2)
(Chan et al, 1999). The role of docetaxel (both as a single agent and
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lin combination) in early or locally advanced breast cancer is
currently being investigated (Gradishar, 1997; Mamounas, 1998;
Costa et al, 1999). These clinical studies are examining the
biological determinants of response and potential resistance to
docetaxel.
This phase II trial was performed to assess the efficacy and
safety of docetaxel as neoadjuvant chemotherapy in patients with
operable stage II–III breast cancer. This involved evaluating
response rates, and more specifically the pathological response
rate.
PATIENTS AND METHODS
In this phase II trial, neoadjuvant chemotherapy was administered
to patients with operable nonmetastatic breast carcinoma. The
primary objective was to assess the pathological response in the
breast and axilla after six infusion cycles of docetaxel. However,
any patient who failed to show evidence of a partial response after
four cycles did not receive the two subsequent infusion cycles.
The eligibility criteria for this study were as follows: age o70
years, histologically proven invasive carcinoma, no metastatic
spread, no prior specific treatment, no prior history of heart
disease, adequate biological functions, World Health Organization
(WHO) performance status of 0 or 1 and written informed consent.
The study was conducted in accordance with the Hong Kong
Amendment of the Declaration of Helsinki and approved by the
Ethics Committee of Auvergne before commencement. The base-
line workup included a complete history and physical examina-
tion, complete blood cell count, blood chemistry analysis, tumour
markers, electrocardiography, chest X-ray, bone scan and liver
ultrasound. Initial staging comprised a complete clinical examina-
tion, mammography and ultrasound; histological diagnosis was
mandatory for the primary tumour and nodes.
Two centres were involved in the recruitment and treatment of
patients. The method of histological diagnosis varied depending on
the centre: needle core biopsy and per cutaneous cytology of
palpable lymph node (Group 1), and surgical biopsy and axillary
dissection (Group 2).
Neoadjuvant chemotherapy
Oral methylprednisolone (48mg) was administered 12, 3 and 1h
before, and 12, 24 and 36h after each cycle of neoadjuvant
chemotherapy. The regimen of docetaxel used was 100mgm
 2
given intravenously over 1h, every 21 days for a total of six cycles.
Blood counts were performed once a week every week during
the 21-day interval. Dose reductions and cycle delay were planned
in case of severe haematological and nonhaematological toxicities.
Subsequent treatments were administered 21 days after the
previous treatment only if the patient’s neutrophil count was
X1500mm
 3 and the platelet count was X100000mm
 3. If either
count was below these levels, treatment was delayed for 1 week and
in case of nonrecovery or nonhaematological toxicity Xgrade 2 at
day 21, the dose of docetaxel given at the next cycle was reduced by
25%.
Locoregional treatment
Surgery consisted of lumpectomy if the residual tumour size was
o3cm, or modified radical mastectomy if the tumour size was
X3cm and in cases of extended intracanalar disease. Surgical
dissection of the axilla was performed after chemotherapy for
Group 1 patients. Radiotherapy was given after surgery with a total
dose of 50–60Gy to the breast, internal mammary lymph nodes
and supraclavicular/high axillary lymph nodes.
Adjuvant therapy
When significant residual disease remained, adjuvant chemother-
apy was considered on an individual basis and left to the clinician’s
judgement. Adjuvant hormonotherapy (tamoxifen) could be given
for 2–5 years to postmenopausal patients presenting oestrogen-
receptor-positive tumours.
Assessment of response
Clinical, mammographic and ultrasound measurements were
recorded before treatment and every two cycles during neoadju-
vant chemotherapy. Clinical responses were evaluated by the
decrease in tumour and node volumes (the product of the two
greatest perpendicular dimensions), and were calculated according
to the WHO recommendations (Miller et al, 1981). A global clinical
response was estimated using the echographic response in the
majority of cases, which accurately reflects the pathological
response (Ferriere et al, 1998). In the other cases, the global
clinical response corresponded to the worst of the responses
obtained by the two other methods of measurement if echographic
response was not available. The pathological response was
independently evaluated after surgical resection of the remaining
tumour, and then finally reviewed by an independent pathologist
using the Chevallier et al (1993) and Sataloff et al (1995)
classifications. As pathological response in axillary nodes could
not be determined in Group 2, Chevallier’s classification was
modified to evaluate response in breast only. This modification
allowed an accurate comparison between the two groups.
Pathological response was then evaluated as follows:
  Class 1: disappearance of all tumour either on macroscopic or
microscopic assessment;
  Class 2: presence of in situ carcinoma;
  Class 3: presence of invasive carcinoma with stromal alteration,
such as sclerosis or fibrosis;
  Class 4: no or few modifications of the tumoral appearance.
Statistical methods
Statistical analysis was descriptive. The comparisons of the
different clinicopathological characteristics, response rates or
other parameters between the two groups gave rise to an
exploratory analysis with a significant P-value of 0.05.
RESULTS
From September 1997 to November 2000, 88 patients entered this
phase II trial. The patients’ median age was 46 years (range, 29–66
years), and 49 women (55.7%) were premenopausal. In all, 86
tumours were X3cm in diameter and two tumours were o3cm,
but located in the central area of the nipple, with a lymph node
status of N0 or N1. The median largest diameter of the primary
tumour was 50mm (range, 20–130mm). Further, tumour
characteristics are shown in Table 1. In all, 44 patients (50.0%)
did not have clinically detectable lymph node involvement at
diagnosis, 61 patients (69.3%) had stage II disease and 27 patients
(30.7%) had stage III disease (20 stage IIIa and seven stage IIIb). In
addition, all patients had at least one other adverse prognostic
factor: clinical lymph involvement (44 N1); high Scarff–Bloom–
Richardson (SBR) grading (42 grade III); aneuploidy (44 cases);
and negative oestrogen and progesterone receptors (28 cases).
At the initial staging, 51 patients underwent needle core biopsy
and node cytology (Group 1), and 37 had surgical biopsy and
axillary dissection (Group 2). As shown in Table 1, the clinical and
pathological characteristics of the two groups were similar. In
Group 2, the median volume of surgical primary biopsy, while not
recorded, has been estimated at 10–20% of the total initial tumour
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27) and the median number of metastatic nodes was five (range,
0–22).
Treatment management
A median number of six cycles (range, 1–6) of neoadjuvant
docetaxel chemotherapy were administered, the median dose being
100mgm
 2 (range, 82–106mgm
 2) in 88 patients. One patient
stopped treatment after five cycles because of septicaemia. The
treatment was also stopped for two patients because of lack of
response at four cycles, as planned by the protocol. However, 24
patients (23 with minor response and one with no change) were
given the two subsequent infusion cycles. Two patients were
considered as noneligible: one patient because of lung metastases
and another because of predominant in situ carcinoma observed at
final review. Of the 86 eligible patients, six were withdrawn from
the study for the following reasons: allergy to docetaxel (n¼3),
lack of response after four cycles (n¼2) and toxicity (n¼1). Thus,
80 patients were included in the per protocol analysis of clinical
response.
In all, 10 patients did not undergo surgery: four because of
disease progression, one because of lack of response after four
cycles, three who were withdrawn from the study (because of drug
allergy) and two who refused surgery (because of a complete
clinical response to docetaxel treatment). Thus, 76 of the 86 eligible
patients underwent surgery (42 in Group 1 and 34 in Group 2) and
were evaluable for pathological response. Breast-conserving
surgery was performed in 55 patients (72.4%) and a modified
radical mastectomy in 21 patients (10 for residual tumour and 11
for in situ carcinoma only). There was no difference between the
two groups in terms of surgical treatment (P¼0.20).
After surgery, all 76 patients received radiotherapy. Subse-
quently, patients received adjuvant chemotherapy at investigator
discretion (n¼37; 48.7%) and/or hormonotherapy with tamoxifen
(n¼34; 44.7%). The adjuvant chemotherapy, which consisted of
six cycles of the FVC or FEC regimens (5-fluorouracil/vinorelbine
or epirubicin/cyclophosphamide), was given to 15 out of 42
patients in Group 1 and to 22 out of 34 patients in Group 2.
Response
As shown in Table 2, response rates (for the per protocol
population) obtained after neoadjuvant docetaxel therapy were
evaluated by clinical, mammographic and ultrasound measure-
ments. The global clinical response corresponded to the echo-
graphic response in the majority of cases or to the worst of the
responses obtained by the two other methods of measurement if
echographic response was not available. Neoadjuvant docetaxel
therapy resulted in an overall clinical response rate of 73.3%,
including 36.0% complete remissions. Overall mammographic and
echographic response rates were 70.0 and 66.7%, respectively. The
overall global response rate was estimated to be 68.4%, with 19.0%
complete responses. The overall global response rate for the
Table 1 Tumour characteristics
No. of patients (%)
Characteristic Overall (n=88) Group 1 (n=51) Group 2 (n=37) P-value
T
T2 53 (60.2) 32 (62.8) 21 (56.8)
T3 28 (31.8) 16 (31.4) 12 (32.4) 0.68
T4
a 7 (8.0) 3 (5.8) 4 (10.8)
N
N0 44 (50.0) 27 (52.9) 17 (46.0) 0.52
N1 44 (50.0) 24 (47.1) 20 (54.0)
Pathology
Invasive ductal 71 (80.7) 42 (82.4) 29 (78.4)
Invasive lobular 12 (13.6) 5 (9.8) 7 (18.9) 0.31
Unspecified invasive carcinoma 5 (5.7) 4 (7.8) 1 (2.7)
Scarff–Bloom–Richardson grading
I 2 (2.3) 1 (2.0) 1 (2.7)
II 39 (44.3) 23 (45.1) 16 (43.2) 0.83
III 42 (47.7) 22 (43.1) 20 (54.1)
Not graded 5 (5.7) 5 (9.8) 0 (0.0)
Hormonal receptors
ER  PgR  28 (31.8) 17 (33.3) 11 (29.8)
ER  PgR+ 3 (3.4) 2 (3.9) 1 (2.7)
ER+ PgR+ 39 (44.4) 19 (37.3) 20 (54.0) 0.77
ER+ PgR  9 (10.2) 5 (9.8) 4 (10.8)
Not classified 9 (10.2) 8 (15.7) 1 (2.7)
Cell kinetics
Presence of an aneuploid population 44 (50.0) 26 (51.0) 18 (48.6) 0.36
Not performed 28 (31.8) 18 (35.3) 10 (27.0)
S-phase X5% 32 (36.4) 24 (47.1) 8 (21.6) 0.28
Not performed 44 (50.0) 20 (39.2) 24 (64.9)
aSome patients with T4 tumours entered this phase II trial. These comprised T4a and T4b tumours and not inflammatory carcinoma. Consequently, it was considered as a minor
protocol violation and these patients were included in the analysis.
ER, oestrogen receptor; PgR, progesterone receptor.
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[CI 95%: 52.6–73.0%], with 17.4% complete responses). There was
no difference in clinical response between Groups 1 and 2,
irrespective of the assessment method used (Po0.35) or the stage
of disease (II vs III, P¼0.96).
Histopathological evaluation
As shown in Table 3, the overall pathological complete response
(pCR) rate was 19.8%, according to Chevallier’s classification
restricted to breast. For patients who had a pCR, the median
tumour size before chemotherapy was 50mm (range, 20–90mm).
Among the patients having a global complete clinical response
prior to surgery, six of 13 operated patients (46.2%) were shown to
have pathological evidence of a residual tumour. Conversely,
among the patients showing an incomplete clinical response
(partial or minor response, no change or progression), eight out of
60 operated patients (13.3%) were classified as pCR according to
Chevallier’s classification restricted to breast. The overall pCR rate
was 35.5% according to Sataloff’s classification. For patients
classed as pCR after docetaxel, median tumour size before
chemotherapy was 50mm (range, 20–90mm). When a global
complete clinical response was obtained before surgery, a residual
pathological tumour was found in 23.1% of these patients (three
out of 13). Among the patients showing incomplete clinical
response, 15 out of 60 (25.0%) had a pCR according to Sataloff’s
classification. Any difference observed between Groups 1 and 2
was not statistically significant (P¼0.06 and 0.35 according to the
restricted Chevallier’s and Sataloff’s classifications, respectively).
Similarly, there was no difference in pathological response,
irrespective of the stage of disease (II vs III, P¼0.64 and 0.43
according to restricted Chevallier’s and Sataloff’s classifications,
respectively).
Follow-up
On 3 July 2001, the median follow-up period was 30.8 months
(range, 8.2–45.5 months). In all, 19 recurrences were observed
(split evenly between Groups 1 and 2), with the median time to
first recurrence being 17.3 months (range, 7.6–24.2 months). Eight
patients (9.3%) have died. In all, 19 recurrences were observed:
  one local in the breast;
  six both local and metastatic (two in lung, two in bone, one in
multiple site and one in cervix nodes);
  and 12 with distant metastases (three in multiple sites, three in
bone, two in lung, two in brain, one in liver and one in uterus).
Table 2 Clinical response rate to neoadjuvant treatment
No. of patients (%)
Clinical
response
Mammographic
response
Echographic
response
Global clinical
response
Overall (n=80)
Complete response (CR) 27 (36.0) 18 (45.0) 11 (17.5) 15 (19.0)
Partial response (PR) 28 (37.3) 10 (25.0) 31 (49.2) 39 (49.4)
Minor response/no change 11 (14.7) 5 (12.5) 11 (17.5) 17 (21.5)
Progression 9 (12.0) 7 (17.5) 10 (15.8) 8 (10.1)
ORR (CR+PR) No. (%; 95 CI) 55 (73.3; 63.3–83.3) 28 (70.0; 55.8–84.2) 42 (66.7; 55.1–78.3) 54 (68.4; 58.1–78.7)
Group 1 (n=45)
ORR (CR+PR) No. (%; 95 CI) 34 (77.2; 64.8–89.6) 18 (66.7; 48.9–84.5) 27 (75.0; 60.9–89.1) 34 (75.6; 63.1–88.1)
Group 2 (n=35)
ORR (CR+PR) No. (%; 95 CI) 21 (67.8; 51.4–84.2) 10 (77.0; 45.0–94.7) 15 (55.5; 36.8–74.2) 20 (58.9; 42.4–75.4)
ORR: overall response rate.
Table 3 Pathological response rate to neoadjuvant treatment
No. of patients (%)
Pathological response Overall (n=76) Group 1 (n=42) Group 2 (n=34)
Restricted Chevallier’s classification
Class 1: no tumour in breast (pCR) 10 (13.2) 3 (7.1) 7 (20.6)
Class 2: in situ carcinoma only 5 (6.6) 2 (4.8) 3 (8.8)
Class 3: invasive carcinoma with alteration 41 (53.9) 26 (61.9) 15 (44.1)
Class 4: unmodified invasive carcinoma 20 (26.3) 11 (26.2) 9 (26.5)
ORR (Classes 1+2) No. (%; 95% CI) 15 (19.8; 10.8–28.8) 5 (11.9; 4.1–25.9) 10 (29.4; 14.1–44.7)
Sataloff’s classification
Class A: complete+quasicomplete response 27 (35.5) 13 (30.9) 14 (41.2)
Class B: partial response 11 (14.5) 6 (14.3) 5 (14.7)
Class C: minor response 18 (23.7) 12 (28.6) 6 (17.7)
Class D: no response 20 (26.3) 11 (26.2) 9 (26.4)
ORR (Class A) No. (%; 95% CI) 27 (35.5; 24.7–46.3) 13 (30.9; 16.9–44.9) 14 (41.2; 24.7–57.7)
ORR: overall response rate.
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chemotherapy, nine (47.7%) had shown an overall global response
(two complete and seven partial responses). Patients with stage III
disease presented more recurrences than patients with stage II
disease (38 vs 15%, P¼0.02). Of the 16 operated patients who
presented recurrences, three (18.8%) had pCR according to the
restricted Chevallier’s classification and seven (43.8%) according
to Sataloff’s classification.
Tolerability of neoadjuvant chemotherapy
From a total of 431 infusion cycles evaluated, the associated
extrahaematological toxicities are shown in Table 4A. Alopecia was
nearly universal, but reversible, except in four patients who
presented with grade IV. No severe cardiac toxicity occurred
despite nine cases of tachycardia with dyspnoea. There were no
significant changes in renal or hepatic parameters. Treatment was
stopped in only three patients who suffered acute allergy to
docetaxel at the beginning of their second infusion.
Table 4B details the haematological toxicities of neoadjuvant
treatment. In all, 12 patients (13.6%) developed febrile neutropenia
(i.e. neutropenia grade IV and fever grade II) which was treated by
antibiotic therapy for a median duration of 7 days (range, 0–10
days). The median duration of a febrile episode was 2 days (range,
2–8 days), and four patients required hospitalisation. Two Group
2 patients with significant haematological toxicity (grade IV febrile
neutropenia) after the second and third cycle were given
haematopoietic growth factor; although no dose reduction or
delay in treatment was required. Grade III–IV neutropenia was
observed in 62 patients (70.5%). In all, 23 patients (26.1%)
developed grade III leucopenia; no patient developed grade IV
leucopenia. One patient (1.1%) with grade IV anaemia required a
blood transfusion, and the dose of docetaxel was reduced by 25%
until the end of treatment. In all, 18 patients (20.5%) developed
grade I–II anaemia. There was no thrombocytopenia, and no other
significant adverse event was observed.
DISCUSSION
The aim of the present phase II study was to assess the efficacy and
tolerability of six cycles of docetaxel at 100mgm
 2 every 21 days
as neoadjuvant chemotherapy in patients with operable breast
cancer.
Although it is perhaps too early to draw definitive conclusions
about the outcome of these patients, neoadjuvant docetaxel
produced very effective tumour response and was well tolerated.
Neoadjuvant docetaxel also offered the possibility of breast
conservation in 72.4% of patients who otherwise would have
undergone a mastectomy. The global clinical response rate (68.4%)
and the pCR rate (19.8 and 35.5% according to the restricted
Chevallier’s and Sataloff’s classifications, respectively) were very
high for monotherapy. They are comparable with the results of
Este ´vez et al (2000), who investigated the response rate of weekly
docetaxel 40mgm
 2 administered for a 12-week period in 54
patients with stage II–III breast cancer. In their preliminary
results, this regimen demonstrated an overall clinical response rate
of 71.0% (complete response, 26.3%; partial response, 44.7%) and
a pCR rate of 21%.
In our study, tumour reduction occurred progressively, with
only 40% of the complete responses having been obtained after
four cycles. After six cycles, our results suggested that this longer
period of monotherapy ensured a good response rate, and in
particular a high pathological response rate. This fact, taken
together with our previous findings (Cure et al, 1997; Ferriere et al,
1998), confirm that a longer period of neoadjuvant chemotherapy
seems to improve the complete response rate, and possibly the rate
of breast conservation. Furthermore, Swain et al (1987) have
reported that the median number of cycles required to reach a
partial or complete response was three and five, respectively.
We noted that the rates of response between the two groups
differed according to the classification system used (11.9 vs 29.4%
in Groups 1 and 2 with the restricted Chevallier’s classification
compared with 30.9 vs 41.2% in Groups 1 and 2 with Sataloff’s
classification), but not according to the stage disease. This gives
prominence to the importance of pathological response evaluation,
particularly in terms of patients’ outcome. In the literature, there
was a small, insignificant advantage in disease-free survival for
patients reaching a pCR after neoadjuvant chemotherapy (Kuerer
et al, 1999). In the present study, of the 16 operated patients who
presented recurrences, three (18.8%) had pCR according to the
restricted Chevallier’s classification and seven (43.8%) according
to Sataloff’s classification. Moreover, patients with stage III disease
presented more recurrences than patients with stage II disease (38
Table 4 (A) Extrahaematological
a and (B) haematological
b toxicities of neoadjuvant treatment
No. of patients by WHO grade (%)
Event I II III IV Total no. of patients (%) No. of events (% of cycles)
(A)
Acute hypersensitivity reactions 0 (0) 39 (44.3) 0 (0) 0 (0) 39 (44.3) 73 (15.1)
Gastrointestinal toxicity 0 (0) 43 (48.9) 0 (0) 0 (0) 43 (48.9) 76 (15.7)
Asthenia 0 (0) 40 (45.5) 0 (0) 0 (0) 40 (45.5) 68 (14.0)
Myalgias and arthralgias 0 (0) 27 (30.7) 1 (1.1)
c 0 (0) 28 (31.8) 50 (10.3)
Cutaneous toxicities 0 (0) 33 (37.5) 0 0 (0) 33 (37.5) 44 (9.1)
Moderate oedema 0 (0) 28 (31.8) 0 0 (0) 28 (31.8) 36 (7.4)
Paresthesias 0 (0) 13 (14.8) 1 (1.1) 0 (0) 14 (15.9) 24 (4.9)
Alopecia 6 (6.8) 16 (18.2) 38 (43.2) 4 (4.6) 64 (72.7) 302 (62.3)
(B)
Neutropenia 2 (2.3) 7 (8.0) 19 (21.6) 43 (48.9) 71 (80.7) 244 (50.3)
Leucopenia 12 (13.6) 31 (35.2) 23 (26.1) 0 (0) 66 (75.0) 199 (41.0)
Anaemia 16 (18.2) 2 (2.3) 0 (0) 1 (1.1) 19 (21.6) 34 (7.0)
Thrombocytopenia 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
aIn total, 89% of cycles were available for extrahaematological toxicities (431 cycles).
bAs a result of some missing blood counts, 56% of cycles were available for leucopenia (262 cycles) and neutropenia (263 cycles), 57% for anaemia (266 cycles) and
thrombocytopenia (265 cycles).
cThe dose of docetaxel given was reduced by 10% until the end of treatment for one patient who presented with severe myalgias.
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lvs 15%, P¼0.02), as previously described (Jacquillat et al, 1990;
Kato et al, 2001; Menard et al, 2002). A total of 49% of patients
received adjuvant chemotherapy and 45% hormonotherapy.
Intensification of the adjuvant treatment with a second non-
crossresistant regimen or high-dose chemotherapy with peripheral
blood stem cells support may be an advantage for patient outcome.
Conversely, for patients who presented a pCR, the identification of
factors predicting the response to treatment and patient outcome
may assist the clinician to more accurately select patients who may
or may not benefit from such a strategy. However, a longer follow-
up period is needed to confirm these results.
Six cycles of docetaxel 100mgm
 2 was safe, with the main
haematological toxicity being neutropenia. As only 56% of cycles
were assessable for haematological toxicity, the rate of significant
neutropenia could be underestimated. Therefore, haematopoietic
growth factors could be used to improve tolerance and avoid
hospitalisation as much as possible. However, no dose reduction
or delay in treatment was performed, and blood counts returned to
normal before the next cycle. No severe extrahaematological
toxicities (WHO grade X3) were observed and the clinical
tolerance was found to be comparable to the usual experience
with docetaxel at this dose (Fumoleau et al, 1995; Chevallier et al,
1995).
Several studies have compared preoperative with postoperative
chemotherapy in patients with operable breast cancer (Mauriac
et al, 1991; Scholl et al, 1994, 1995; Powles et al, 1995; Mamounas,
1998). The principal aim of these trials was to determine whether
preoperative chemotherapy more effectively prolongs disease-free
and overall survival than the same chemotherapy given post-
operatively. Neoadjuvant therapy seemed to show better results in
terms of rate of response to treatment and a reduction in the
requirement for mastectomy. However, the results for survival
rates are conflicting. Scholl et al (1994) initially observed a
statistically significant difference in survival in favour of the
neoadjuvant chemotherapy group, but they reported later that this
advantage became insignificant (Scholl et al, 1995). Mauriac et al
(1991) concluded that survival rates were identical in their two
treatment groups. A study by Powles et al (1995) confirmed
previous reports of a high rate of response to neoadjuvant therapy,
but the follow-up period was too brief to evaluate the relapse rate
or survival duration. The National Surgical Adjuvant Breast
Project (NSABP) study B-18 demonstrated that in 1523 patients
with operable breast cancer, preoperative chemotherapy resulted
in high rates of clinical response, axillary nodal downstaging and
increased rates of breast preservation (Mamounas, 1998). A low
rate of pCR was found, but it was calculated from patients who had
a complete clinical response and may not, therefore, be
representative of all the patients who received preoperative
chemotherapy. The authors concluded that there were no
differences in progression-free or overall survival between the
two groups. Hence, even if these studies showed that neoadjuvant
chemotherapy did not demonstrate a greater survival, this strategy
offers the possibility of downstaging and the avoidance of
mastectomy in 75–80% of bulky tumours.
With the development of new taxanes, and the demonstration of
the significant antitumour activity in patients with advanced breast
cancer (Ravdin et al, 1995; Valero et al, 1995; Marty et al, 1997;
Valero, 1997), clinical research is now focused on integrating
docetaxel into combination regimens and into neoadjuvant and
adjuvant schedules for patients with operable breast cancer. The
biological determinants of response and resistance to docetaxel are
also being examined (Powles et al, 1995; O’Leary et al, 1998). A
very important question is whether there is true synergy between
two or more drugs that are used simultaneously or successively.
Several large phase II and randomised phase III trials are currently
evaluating docetaxel used in combination, and/or sequentially, in
the preoperative setting (Gradishar, 1997, 1998; Mamounas, 1998;
Costa et al, 1999).
In a study by Gradishar et al (1997), 43 stage III patients
received four cycles of docetaxel 100mgm
 2 on a 3-weekly
schedule, followed by surgery, then four cycles of adjuvant
doxorubicin plus cyclophosphamide, and also tamoxifen if the
tumour was hormone-receptor positive or the patient was aged
450 years. The overall clinical response rate was 78% (complete
response, 14%; partial response, 64%). Of the six patients with
complete clinical response, only one (2%) showed pCR. von
Minckwitz et al (1999) treated 42 patients with stage III operable
breast cancer with four cycles of docetaxel 75mgm
 2 plus
doxorubicin 50mgm
 2. An overall response rate of 93% (complete
response, 33%; partial response, 60%) and a pCR rate of 5% were
observed. The same regimen was administered to nine patients
with locally advanced breast cancer (LABC). Preliminary results
showed an overall response rate of 100% (complete response, 11%;
partial response, 89%) with one patient (11%) showing a partial
pathological response and one patient (11%) showing a minor
pathological response. The Aberdeen Breast Study group is
conducting a phase III trial in patients with stage III or LABC
using docetaxel in sequential fashion following an anthracycline-
based cyclophosphamide/doxorubicin/vincristin/prednisolone
(CVAP) regimen (Smith et al, 2002). In patients with tumours
unresponsive to CVAP, docetaxel induced a 55% clinical response
and a 2% pCR rates. For patients with initially responsive tumours,
the sequential use of docetaxel also gave better results (94%
clinical response and 34% pCR rates) than further cycles of
CVAP (66% clinical response and 16% pCR rates). The efficacy
of docetaxel over CVAP seems to have been demonstrated
(P¼0.001 for clinical response and P¼0.04 for pathological
response).
In conclusion, the results of the present study show that
neoadjuvant chemotherapy with docetaxel is both effective and
well tolerated in patients with early-stage operable breast cancer.
In addition, neoadjuvant chemotherapy with docetaxel may
improve breast-conservation rates. Randomised phase III studies
are required to confirm the benefits of neoadjuvant vs post-
operative adjuvant chemotherapy.
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